Double-Expressor Lymphoma: Prognostic Impact and Treatment Efficacy Meta-Analysis

A 2026 meta-analysis synthesizing evidence from 66 studies with 9,808 patients quantifies the poor prognosis of double-expressor lymphoma (DEL). The study, authored by Hao Guan, also includes a network meta-analysis of 13 treatment studies involving 1,803 patients to compare novel therapeutic regimens.

Use Cases

• Quantifying survival hazard ratios for DEL versus non-DEL based on reported progression-free and overall survival data.
• Identifying prognostic factors within DEL, such as International Prognostic Index or TP53 mutation status, mentioned in the results.
• Comparing the efficacy and safety of novel treatment regimens like Z+R-CHOP and Ven-R-CHOP through network meta-analysis results.

Strengths

• Evidence synthesis is based on 66 studies encompassing 9,808 patients, providing a substantial evidence base.
• The network meta-analysis includes data from 13 treatment studies covering 1,803 patients.
• Specific hazard ratios with confidence intervals are reported for key outcomes like progression-free survival (1.78) and overall survival (1.90).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary data format is a DOCX document, which may require parsing to extract structured data.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of published studies.

Freshness

Last updated 2026-05-21 04:36:22; freshness should be verified.